Postpartum Depression

Positive Phase 3 Test of Rapid-Acting Oral Medicine for Postpartum Depression
An investigational medicine called zuranolone has generated significant, rapid, and enduring symptom reduction in women with postpartum depression. The drug was compared with placebo in a phase 3… Read More
Postpartum CBT for Depressed Moms May Help Lower Emotion-Regulation Risks in Infants
Is it possible to disrupt the process by which a mother can transmit risk for psychiatric disorders to her offspring? New research suggests one way in which this may be possible. Read More
Impact of Mother’s Depressive Symptoms Just Before and After Childbirth Upon Child’s Brain Development
Past research has established a clear connection between maternal depression and risk of adverse outcomes in newborns, for instance a higher risk of the child having low birthweight. Over the longer… Read More
The First Drug Treatment To Specifically Relieve Postpartum Depression Is Approved
On March 19, 2019, the U.S. Food and Drug Administration approved the first-ever drug specifically designed to alleviate the symptoms of postpartum depression. The drug, called brexanolone, acts… Read More
Pregnancy May Alter Brain’s Immune Function
During pregnancy and for some time after giving birth, a woman’s immune response in the brain may be tuned down, a new study in rats suggests. This research was published in the November 2017 issue… Read More